374
Participants
Start Date
April 30, 2009
Primary Completion Date
December 31, 2009
Study Completion Date
December 31, 2009
MVI 100
Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
MVI 150
Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
MVI 200
Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Temple University Hospital, Philadelphia
Forsyth Medical Center, Winston-Salem
Duke University Medical Center, Durham
Greenville Hospital System, Greenville
University of Tennesse Medical Center, Knoxville
University of Texas Health Sciences Center at Houston, Houston
Precision Trials, Phoenix
Tuscon Medical Center, Tucson
University of New Mexico Medical Center, Albuquerque
Long Beach Memorial Medical Center, Long Beach
UCI Medical Center, Orange
Lead Sponsor
Ferring Pharmaceuticals
INDUSTRY